Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

CureVac (CVAC) and GSK (GSK) to receive $740M and other payments in a settlement with Pfizer (PFE) and BioNTech (BNTX) over ...

The complicated legal wrangling has been brought to a close after CureVac and BioNTech settled their mRNA patent litigation ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

The settlement ends US mRNA patent disputes involving COVID-19 and influenza vaccines, while positioning GSK for additional ...

American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain's GSK and Germany's CureVac $740 ...

The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an ...

GSK (GSK) announces that, in connection with the mRNA patent settlement reached between CureVac (CVAC) and BioNTech on 7 August 2025, the Company ...

American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain’s GSK and Germany’s CureVac US$740 ...

GSK said the upfront settlement amount will be recorded as other operating income in its financial results as an adjusting item in the income statement in the third quarter of 2025. The 2025 and ...

The tussle had centred on the development of mRNA jab technology, which was at the forefront of the fight against Covid-19.